SCHEMBL1471547

SCHEMBL1471547

C=CCC(OCC(C)CC)C(=O)O

nearest known ligand 0.35

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.35
GRIK1 P39086 2/20 0.33
GRIK2 Q13002 2/20 0.33
CYP2C19 P33261 1/20 0.32
CPA1 P15085 1/20 0.32
TSHR P16473 1/20 0.32
FFAR1 O14842 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16859599 0.81
SCHEMBL7073739 0.80 PPARA (0.42) GRIK1GRIK2CYP2C19CPA1
SCHEMBL273058 0.74 TDP1 (0.42) GRIK1GRIK2CYP2C19CPA1TSHR
SCHEMBL28237464 0.72 TSHR (0.41) TSHR
SCHEMBL28010130 0.72 GRIK1 (0.37) GRIK1GRIK2CYP2C19CPA1TSHR
SCHEMBL28575140 0.72 GRIK1 (0.37) MAPTGRIK1GRIK2CYP2C19CPA1
SCHEMBL5718445 0.71 MAPT (0.42) MAPTFFAR1
SCHEMBL19974352 0.71 MAPT (0.42) MAPTFFAR1
SCHEMBL14780782 0.71
SCHEMBL11034749 0.71 GRIK1 (0.42) MAPTGRIK1GRIK2CYP2C19CPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10918579-B2 Density balanced high impact perfume microcapsules FIRMENICH SA (CH) 2021-02-16 US claimed
US-20150182656-A1 Perfume Compositions GIVAUDAN S.A. (CH) 2015-07-02 US claimed
US-20150079017-A1 Perfume Compositions GIVAUDAN S.A. (CH) 2015-03-19 US claimed
US-20140235520-A1 Perfume Compositions GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2014-08-21 US claimed
US-20130230479-A1 Perfume Compositions GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2013-09-05 US claimed
US-20130039876-A1 Perfume Compositions GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2013-02-14 US claimed
US-20130039877-A1 Perfume Compositions GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2013-02-14 US claimed
EP-2049638-B1 PERFUME COMPOSITIONS GIVAUDAN NEDERLAND SERVICES BV (NL) 2012-10-03 EP claimed
EP-2049637-B1 PERFUME COMPOSITIONS GIVAUDAN NEDERLAND SERVICES BV (NL) 2012-05-30 EP claimed
EP-1869150-B1 PERFUME COMPOSITIONS GIVAUDAN NEDERLAND SERVICES BV (NL) 2012-05-30 EP claimed
US-20110182832-A1 PERFUME COMPOSITIONS QUEST INTERNATIONAL SERVICES B.V. (NL) 2011-07-28 US claimed
US-20090263344-A1 Perfume Compositions GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2009-10-22 US claimed
US-20090257974-A1 Perfume Compositions GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2009-10-15 US claimed
WO-2009052643-A1 ANTI-MALODOUR COMPOSITIONS GIVAUDAN SA (CH) 2009-04-30 WO claimed
EP-2049637-A1 PERFUME COMPOSITIONS Givaudan Nederland Services B.V. (NL) 2009-04-22 EP claimed
EP-2049638-A1 PERFUME COMPOSITIONS Givaudan Nederland Services B.V. (NL) 2009-04-22 EP claimed
WO-2008023142-A1 PERFUME COMPOSITIONS GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2008-02-28 WO claimed
WO-2008017820-A1 PERFUME COMPOSITIONS GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2008-02-14 WO claimed
US-20260085253-A1 LILY OF THE VALLEY ODORANT FIRMENICH & CIE (CH) 2026-03-26 US disclosed
WO-2008017820-A1 PERFUME COMPOSITIONS GIVAUDAN NEDERLAND SERVICES B.V. (NL) 2008-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085253-A1 LILY OF THE VALLEY ODORANT PIR, ALG3, ENY2 MAPT 1117/4885GRIK1 2321/4885GRIK2 1704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.